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Antimicrobial Activity of CHIR-090, an Inhibitor of Lipopolysaccharide
Biosynthesis, against the Burkholderia cepacia Complex
A striking characteristic of cystic fibrosis (CF) is susceptibil-
ity to life-limiting bacterial infections of the respiratory tract
(13, 26). Members of the Burkholderia cepacia complex are a
particular cause of anxiety to CF individuals (8, 14, 23) since
they display high resistance to antibiotics and biocides (3, 32),
possibly linked to their relatively large (8- to 9-Mbp) ge-
nomes (16). At present, the B. cepacia complex consists of 17
species, the majority of which have been recovered from CF
patients (4, 10, 11, 36, 37, 40). As an aid to B. cepacia complex
studies, two panels of B. cepacia complex reference isolates
(Table 1) have been assembled that include B. multivorans and
B. cenocepacia strains, the two most prevalent species respon-
sible for CF infections (11, 22). A promising target for the
development of new antibiotics against multiresistant Gram-
negative pathogens are the lipopolysaccharide (LPS) biosyn-
thetic and modification pathways (27, 29, 30, 39). LPS (also
known as endotoxin) is the major component of the bacterial
outer membrane. Nine enzymes are required to form the
basic core Kdo2-lipid A, and the first six of these enzymes
are essential in Escherichia coli. Also, we discovered that a
putative locus involved in Ara4N synthesis and LPS modi-
fication was essential to B. cenocepacia (28). The metal-
dependent UDP-[3-O-(R-3-hydroxymyristoyl)]-N-acetylglu-
cosamine deacetylase (LpxC) (Fig. 1) that catalyzes the
second step in lipid A biosynthesis (18, 41) has been targeted
and, like many metalloenzymes, can be inhibited by hydroxam-
ate-containing compounds (7, 9, 17). The synthetic antibiotic
CHIR-090 (Fig. 1) (N-aroyl-L-threonine hydroxamic acid [in-
ternational patent WO 2004/062601 A2]) (1) has been shown
to be a slow, tight-binding inhibitor of the LpxCs from
different species (5, 6, 24) and displayed good antimicrobial
activity against several Gram-negative bacteria (6).
We determined the activity of CHIR-090 against the B.
cepacia complex (Table 1) initially by disc diffusion growth
inhibition assay according to published guidelines (2). Individ-
ual isolates displayed remarkable differences in susceptibility
to CHIR-090, even within a single species. Interestingly,
CHIR-090 was active against all representative strains of B.
multivorans, B. vietnamiensis, B. dolosa, and B. ambifaria. We
prepared a panel of clinically relevant B. multivorans strains for
MIC determination and included E. coli and Pseudomonas
aeruginosa (Table 2). The CHIR-090 MICs were strain depen-
dent, and the values obtained ranged from 0.1 to 100 g/ml.
The LPSs from a number of Burkholderia species display
unique structural and inflammatory properties (12, 33); how-
ever, there appears to be no correlation between CHIR-090
activity and the LPS profiles of individual strains. For example,
CHIR-090 is not active against smooth LPS strain B. cenoce-
pacia K56-2 or its deep-rough LPS derivative SAL1 (20). A
BLAST sequence analysis of the Burkholderia genomes (Burk-
holderia Genome Database) revealed that the LpxC genes are
highly conserved and display high sequence homology to
LpxCs from P. aeruginosa and E. coli; thus, the reason(s) why
CHIR-090 is not active against certain members of the B.
cepacia complex remains to be clarified. Our study reports the
potential of therapeutic agents against Burkholderia targeted at
LPS biosynthesis. Such agents may, possibly in combination
TABLE 1. Inhibition of strains of Burkholderia genomovars I to IX
by CHIR-090
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a The values shown are CHIR-090 inhibition zones in the disc diffusion assay
(40 g/disc).
b —, CHIR-090 gave no zone of growth inhibition with this particular strain.
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with nanoemulsions (19), provide a breakthrough in the treat-
ment of CF-related infections.
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ATCC 27853 ATCC 0.78 3.13
ATCC 10145 ATCC 0.78 3.13
B. multivorans (II)
C5393 Vancouver CF clinic, 21 3.13 100
LMG 13010 Belgian CF clinic, 31 100 100
C1576 Glasgow epidemic, 38 12.5 100
CF-A1-1 Cardiff CF clinic, 25 1.56 100
JTC CGDb patient, 34 1.56 100
C1962 Brain abscess, 15 3.13 100
ATCC 17616 Environmental strain, 35 6.25 50
249-2 Derived from ATCC
17616
0.10 100
a The antibiotic concentrations used ranged from 0 to 100 g/ml.
b CGD, chronic granulomatous disease.
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